1] Smooth Muscle Research Group and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada [2] Smooth Muscle Research Group and Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Smooth Muscle Research Group and Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Kidney Int. 2015 Feb;87(2):370-81. doi: 10.1038/ki.2014.284. Epub 2014 Aug 20.
Bolus administration of endothelin-1 elicits long-lasting renal afferent arteriolar vasoconstriction, in contrast to transient constriction induced by angiotensin II. Vasoconstriction is generally evoked by myosin regulatory light chain (LC20) phosphorylation at Ser19 by myosin light chain kinase (MLCK), which is enhanced by Rho-associated kinase (ROCK)-mediated inhibition of myosin light chain phosphatase (MLCP). LC20 can be diphosphorylated at Ser19 and Thr18, resulting in reduced rates of dephosphorylation and relaxation. Here we tested whether LC20 diphosphorylation contributes to sustained endothelin-1 but not transient angiotensin II-induced vasoconstriction. Endothelin-1 treatment of isolated arterioles elicited a concentration- and time-dependent increase in LC20 diphosphorylation at Thr18 and Ser19. Inhibition of MLCK or ROCK reduced endothelin-1-evoked LC20 mono- and diphosphorylation. Pretreatment with an ETB but not an ETA receptor antagonist abolished LC20 diphosphorylation, and an ETB receptor agonist induced LC20 diphosphorylation. In contrast, angiotensin II caused phosphorylation exclusively at Ser19. Thus, endothelin-1 and angiotensin II induce afferent arteriolar constriction via LC20 phosphorylation at Ser19 due to calcium activation of MLCK and ROCK-mediated inhibition of MLCP. Endothelin-1, but not angiotensin II, induces phosphorylation of LC20 at Thr18. This could contribute to the prolonged vasoconstrictor response to endothelin-1.
内皮素-1 推注给药会引起持久的肾入球小动脉收缩,与血管紧张素 II 引起的短暂收缩相反。血管收缩通常是由肌球蛋白轻链激酶 (MLCK) 使肌球蛋白调节轻链 (LC20) 在丝氨酸 19 磷酸化而引起的,肌球蛋白轻链磷酸酶 (MLCP) 被 Rho 相关激酶 (ROCK) 介导的抑制增强。LC20 可以在丝氨酸 19 和苏氨酸 18 处双磷酸化,导致去磷酸化和松弛速度降低。在这里,我们测试了 LC20 双磷酸化是否有助于持续的内皮素-1 而不是短暂的血管紧张素 II 引起的血管收缩。分离的小动脉内皮素-1 处理会引起 LC20 在 Thr18 和 Ser19 处的浓度和时间依赖性双磷酸化增加。MLCK 或 ROCK 的抑制减少了内皮素-1 引起的 LC20 单磷酸化和双磷酸化。ETB 而不是 ETA 受体拮抗剂的预处理消除了 LC20 双磷酸化,并且 ETB 受体激动剂诱导了 LC20 双磷酸化。相比之下,血管紧张素 II 仅引起 Ser19 磷酸化。因此,内皮素-1 和血管紧张素 II 通过钙激活 MLCK 和 ROCK 介导的 MLCP 抑制引起 LC20 在 Ser19 处的磷酸化,从而引起入球小动脉收缩。内皮素-1 而不是血管紧张素 II 引起 LC20 在 Thr18 处的磷酸化。这可能有助于内皮素-1 引起的血管收缩反应延长。